9th IPF Summit Hilton Boston Park Plaza, Boston
The pulmonary fibrosis field is entering a pivotal moment. Boehringer Ingelheim’s positive Phase 3 trials for nerandomilast, poised to be the first new approval in over a decade, have injected long-awaited momentum into the space. PureTech Health, Endeavor BioMedicines, Insilico Medicine, Bristol Myers Squibb, and United Therapeutics are rapidly advancing through mid- to late-stage trials, signaling a renewed era of therapeutic possibility. Yet 2025 has also brought setbacks, including Pliant’s discontinuation of the BEACON-IPF study for bexotegrast due to safety concerns, underscoring the complexity of treating this disease.
⌛ Event Dates & Venue
💸 Website & Tickets

Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 4197.00, Drug Developer Pricing - Conference Only: USD 2999.00, Academic Pricing - Conference + Pre-Conference Workshop Day: USD 3597.00, Academic Pricing - Conference Only: USD 2599.00, Service Pricing - Conference + Pre-Conference Workshop Day: USD 5097.00, Service Pricing - Conference Only: USD 3699.00
Advertisements